← Back to patent-cliff list
Molnupiravir
Tier C — Watch / tradeMolnupiravir
-
Originator
2021
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：RdRp
Brand：Molxvir, Lagevrio, Movfor, LAGEVRIO
Indications (approved)：COVID-19
Regional status
US
Phase III
2020-10-19
EU
Approved
2021-11-04
China
Approved
2022-12-30
Japan
Approved
2021-12-24
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Molnupiravir?
Approved indications include: COVID-19.
When does the Molnupiravir patent expire?
No public expiry year is available for Molnupiravir yet; this page updates once verified.
How do I get a quote for Molnupiravir intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27